Valcyte Related Clinical Trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients [Completed]
Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition [Completed]
Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition [Completed]
Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation [Terminated]
Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients [Completed]
Valganciclovir in Congenital CMV Infants [Completed]
Valganciclovir to Reduce T Cell Activation in HIV Infection [Completed]
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation [Recruiting]
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections [Completed]
Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection [Active, not recruiting]
Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease [Withdrawn]
Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. [Completed]
Suppression of Oral HHV8 Shedding With Valganciclovir [Completed]
A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients [Completed]
Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV) [Active, not recruiting]
Congenital CMV and Hearing Loss in Children up to 4 Years of Age: Treating With Valganciclovir Therapy [Recruiting]
Efficacy and Safety of ValcyteŽ as an Add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection [Active, not recruiting]
WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (ValcyteŽ) at a Dose of 900mg in Kidney Transplant Recipients [Terminated]
Oral Valganciclovir Versus Valacyclovir [Completed]
Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation [Completed]
Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant [Terminated]
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment [Recruiting]
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial [Terminated]
VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients [Completed]
A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients [Completed]
A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation [Active, not recruiting]
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients [Completed]
Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients [Completed]
Pharmacokinetics of Mmf and Valganciclovir [Recruiting]
Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT) [Completed]
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma [Completed]
A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age [Completed]
Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection [Active, not recruiting]
A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis. [Completed]
MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus [Terminated]
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders [Terminated]
Study of Prophylactic Vs Preemptive Valganciclovir [Completed]
An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients [Completed]
CerticanŽ (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients [Recruiting]
Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients [Completed]
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies [Terminated]
Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients [Recruiting]
TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant [Completed]
Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation [Completed]
Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer [Active, not recruiting]
Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy [Recruiting]
A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS [Completed]
The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection. [Completed]
Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV [Completed]
SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipients [Not yet recruiting]
Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients [Not yet recruiting]
Cytomegalovirus Control in Critical Care [Completed]
Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation [Completed]
An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls [Recruiting]
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant [Completed]
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity [Recruiting]
Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) [Completed]
Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure [Recruiting]
Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients [Completed]
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma [Completed]
Antiviral Treatment of Chronic Lymphocytic Leukemia [Completed]
B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure [No longer available]
A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes [Completed]
Tocilizumab for KSHV-Associated Multicentric Castleman Disease [Recruiting]
Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation [Recruiting]
Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center [Not yet recruiting]
Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients [Recruiting]
Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults [Completed]
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients [Completed]
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients [Completed]
Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients [Completed]
Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients [Completed]
Alternate Donor Study of Pre-Emptive Cellular Therapy [Completed]
Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study [Completed]
|